• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20042 / SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application...

SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™

1 June 2004/in 2004, News

SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2004-06-01 14:28:562016-11-28 14:29:22SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS Link to: SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS SuperGen Provides Additional Analysis of Response Data from Phase III Study... Link to: SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin for Treatment of Advanced Solid Tumors Link to: SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin for Treatment of Advanced Solid Tumors SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok